Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2009

View Archived Issues

Final results of two studies detail anti-arthritic activity of CP-690550

Humanized mAb GSK-3152314 developed for RA therapy is safe in healthy subjects

Sosei enters definitive distribution agreement with Aska for contraceptive NorLevo

Noxxon initiates first-in-human clinical trial with NOX-A12

The European Commission approves Yondelis for ovarian cancer

Amylin and Takeda enter into worldwide agreement for compounds for obesity

Dana-Farber and InteRNA to codevelop miRNA-based cancer therapy

AEterna Zentaris reports results from phase II trial of AEZS-108 in ovarian cancer

Grazax allergy immunotherapy tablet meets primary endpoint in phase III trial

TransTech Pharma discloses GLP-1 receptor agonists for the treatment of diabetes

Seaside initiates phase I clinical trial of STX-107 in fragile X syndrome

Juvaris begins enrollment in phase II trial of JVRS-100 adjuvant for influenza vaccines

EnzymeRx initiates enrollment in phase I clinical study of uricase-PEG 20

Valeant completes filing of retigabine in the U.S. and Europe

SymBio submits NDA in Japan for SyB L-0501 for NHL and mantle cell lymphoma

Mundipharma completes phase III clinical study of Flutiform in asthma

FDA issues complete response letter regarding GTx's NDA for toremifene

Cathepsin S inhibitor VBY-285 reduces chemotherapy-induced neuropathic pain in rats

Novel AD candidate AMG-0683 reduces Abeta levels in rat brain and CSF

Preliminary clinical data show promise for inecalcitol in prostate cancer

No additional benefit with cyclophosphamide as add-on to steroids in HSP therapy

GI-5005 vaccine plus peginterferon/ribavirin improves treatment response in HCV

CB1 receptor agonists discovered at Pfizer for the treatment of pain

Radius patents novel SARMS for the treatment of cancer

Amira Pharmaceuticals describes CRTH2 antagonists for asthma therapy

Pfizer and Medivation initiate two phase III trials of dimebon in Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...